Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN060 in patients with essential hypertension
NCT07191899Phase 1Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in essential hypertension comparing KN060 with Placebo (2 arms). Primary endpoint: Mean Systolic Blood Pressure Change From Baseline in 24hABPM at 12 weeks. Started Aug 2025; status: recruiting.
02
Drugs
lofacimig
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07191899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191899.